Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Surgeon General
  • Cigna’s ACA Exit
  • Visa Program
  • Medicaid Work Requirements
  • Gavin Newsom

TRENDING TOPICS:

  • Surgeon General
  • Cigna's ACA Exit
  • Visa Program
  • Medicaid Work Requirements
  • Gavin Newsom

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Wednesday, Sep 25 2024

Full Issue

FDA Approves Drug For Rare Niemann-Pick Disease Type C

The genetic disorder, which is fatal, affects the nervous system and other organs — IntraBio's drug Aqneursa was shown to help reduce symptoms compared to a placebo. Separately, Amgen reported success for eczema and myasthenia gravis treatments.

Reuters: US FDA Approves IntraBio's Drug For Rare Genetic Disease

The U.S. Food and Drug Administration approved IntraBio's drug for a rare and fatal genetic disorder, the health regulator said on Tuesday, just days after the agency cleared the first treatment for the disease. Niemann-Pick disease type C (NPC) is a rare genetic disorder that affects the nervous system and other organs, causing physical and mental disabilities such as speech issues, difficulties with swallowing and coordination, clumsiness and others over time. (9/24)

Stat: Amgen Reports Success For Eczema And Myasthenia Gravis Treatments

Amgen on Tuesday reported that a pair of antibody drugs it is developing as treatments for immune-mediated diseases succeeded in late-stage trials, but the therapies did not clearly beat existing competitors on the market. (Wosen and DeAngelis, 9/24)

Axios: AI's Latest Trick: Repurposing Old Drugs For Rare Disease

A new artificial intelligence tool could supercharge efforts to find new uses for old drugs, particularly rare diseases without a Food and Drug Administration-approved treatment. The Harvard Medical School researchers behind the tool, called TxGNN, write today in Nature Medicine that it can identify candidates for 17,000 conditions — the largest number of diseases that any single AI model can handle to date. (Reed, 9/25)

The New York Times: Anti-Aging Enthusiasts Are Taking a Pill to Extend Their Lives. Will It Work?

In March, Robert Berger, 69, a self-proclaimed “better-living-through-chemistry type of person,” started taking a small dose of rapamycin once a week with the goal of increasing his “health span” — the amount of time he might live without serious disease. Rapamycin is typically prescribed to organ transplant patients to suppress their immune systems. But many scientists and longevity seekers like Mr. Berger think the drug can do much more than that: They say it can delay aging and age-related diseases. (Smith, 9/24)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Friday, May 1
  • Thursday, April 30
  • Wednesday, April 29
  • Tuesday, April 28
  • Monday, April 27
  • Friday, April 24
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF